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HemichannelDefects in several different connexins have been associated with several different diseases. The most common
of these is deafness, where a few mutations in connexin (Cx) 26 have been found to contribute to over 50% of
the incidence of non-syndromic deafness in different human populations. Other mutations in Cx26 or Cx30
have also been associated with various skin phenotypes linked to deafness (palmoplanta keratoderma,
Bart–Pumphrey syndrome, Vohwinkel syndrome, keratitis–ichthyosis–deafness syndrome, etc.). The large
array of disease mutants offers unique opportunities to gain insights into the underlying function of gap junc-
tion proteins and their channels in the normal and pathogenic physiologies of the cochlea and epidermis. This
review focuses on those mutants where the impact on channel function has been assessed, and correlated
with the disease phenotype, or organ function in knock-out mouse models. These approaches have provided
evidence supporting a role of gap junctions and hemichannels in K+ removal and recycling in the ear, as well
as possible roles for nutrient passage, in the cochlea. In contrast, increases in hemichannel opening leading to in-
creased cell death, were associated with several keratitis–ichthyosis–deafness syndrome skin disease/hearing
mutants. In addition to providing clues for therapeutic strategies, these ﬁndings allow us to better understand
the speciﬁc functions of connexin channels that are important for normal tissue function. This article is part of
a Special Issue entitled: The communicating junctions, roles and dysfunctions.
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As the sole mediators of the direct exchange of ions, signaling mol-
ecules (cAMP, IP3, etc.), energy sources (ATP, GTP), reducing/oxidizing
agents (glutathione) and nutrients (glucose, amino acids) between
cells, it is not surprising that gap junctions have been implicated in
the homeostatic and integrative functions of most tissues. However,
unlike other membrane channels and transporters, where the nature
of the signals involved is well established, it has been hard to deﬁne
the speciﬁc underlying mechanisms of this integration of cell behav-
ior, as the identiﬁcation of the relevant gap junction permeants has
proven challenging for these relatively non-speciﬁc channels. None-
theless, extensive evidence from several in vitro and mouse studies
has shown that different connexin isotypes cannot substitute for one
another and create normal tissue functions, demonstrating that not
all connexins are created equal. The picture becomes even more com-
plex with the growing recognition that at least some connexin pro-
teins can also form open hemichannels on the plasma membrane
under certain physiological conditions (reduced extracellular Ca++,
depolarizing membrane potentials and membrane stretch — [1–3]).
This would provide one of the few known routes for the exchange of
larger molecules between the cytoplasm and extracellular space. In
fact, they have been implicated in ATP release associated with Ca2+
wave propagation [4], nicotinamide-adenine dinucleotide (NAD+) re-
lease to allow access to CD38 and conversion to cADP ribose [5], and
PGE2 release to regulate bone formation [6]. In addition, the cytoplas-
mic domains of several connexins, particularly Cx43, have been shown
to interact with a number of important structural and signaling mole-
cules (reviewed in Ref. [7]), suggesting additional pathways by which
they may be able to inﬂuence cell behavior.
Given the broad spectrumof roles connexins can play in integration of
cell behavior, it is not surprising that mutations associated with several
members of the connexin family have been associated with a diverse
array of diseases affecting many tissues (neuronal myelin, eye (lens)
and ear (cochlea) structure and function, connective tissue, cardiac func-
tion, etc.; reviewed in Ref. [8]). These diseases not only challenge us to
seek the means to alleviate their symptoms, but also provide a unique
window into understanding the speciﬁc functions of connexin proteins
in different tissues. Nature has provided us a host ofmutations that affect
different aspects of channel functions. When these are associated with
speciﬁc patient phenotypes, and accompanying mechanistic studies in
mice engineered to express the defective proteins, we take major steps
towards deﬁning their mechanism of action in speciﬁc tissues. This be-
comes increasingly important in the case of gap junctions, as most of
the powerful genetic model systems (e.g. Drosophila melanogaster and
Caenorhabditis elegans), which have provided invaluable insights into
function in other gene families, are of limited use in the study of the
connexin gene family, as gap junctions in most invertebrates are com-
posed of a topologically similar, but unrelated family called innexins.
The relatives of innexins in vertebrates, a 3‐gene family called the
pannexins, appear not to form gap junctions, but either forms surface
hemichannels or plays as yet undeﬁned roles in intracellular compart-
ments [9,10].
Perhaps the most widely studied example of connexin‐associated
disease has been the role of Cx26 (GJB2), and to a lesser extent the
other β-connexins Cx30 (GJB6), 30.3 (GJB4) and 31(GJB3), in hearing
loss. This is in large part due to the sheer frequency of these muta-
tions, ﬁve of which can account for large fractions of all cases of
prelingual, non-syndromic deafness in different human populations.
In addition to these primarily recessive mutants associated with
non-syndromic deafness, other mutations with dominant inheritance
patterns have been associated with combined deafness and skin dis-
ease phenotypes, and yet others cause problems only in the skin.
This constellation of mutations, affecting only 3–4 closely related pro-
teins, provides a unique set of “controls” that help in dissecting out
which functions of connexins are critical in the two tissues. Therehave been several excellent reviews on this topic over the last few
years [11–13]. Thus, rather than providing an exhaustive listing of
all cases of connexin‐associated deafness and skin disease, we will
focus on mutations in each of the above disease types where we
have some information on the functional consequences, and attempt
to summarize what this has taught us about the likely roles of gap
junctions in maintaining normal cochlear and skin functions.
2. Connexin phenotypes affecting the ear and epidermis
2.1. Cx26 mutations and non-syndromic hearing loss (NSHL)
1 in every 1000 children could suffer from congenital hearing loss
[14], which can be either syndromic or non-syndromic. Non-syndromic
hearing loss (NSHL) is characterized by sensorineural hearing loss in
the absence of other symptoms, while syndromic hearing loss affects
other organ systems, primarily the skin in the case of connexins. The
loci linked to non-syndromic hearing loss could be categorized into dom-
inant (DFNA), recessive (DFNB), X-linked (NFDX), and Y-linked (NFDY).
Over 80 loci have been linked to nonsyndromic hearing loss, covering
a large spectrum of molecules critical for the normal function of the ear
[15]. However, mutations in GJB2 (encoding Cx26) account for half of
all congenital and autosomal recessive non-syndromic hearing loss
(DFNB1) in every tested population [16–24]. To date, there have been
over 150mutations found in the GJB2 gene. Among thesemutations, de-
letionmutationswhich cause frameshift and/or truncation of the protein
at an early stop codon are themost frequent. Severalmutations are pres-
ent with high prevalence, but with different frequencies in different
populations. 35delG [17–22,24], 167delT [23,25], 235delC [16,26],
R143W [27] and W24X [28,29] mutations are, respectively, prevalent
in Caucasian, Jewish, east Asian, Ghanan, and Indian/Romani gypsy
populations. These mutations have carrier frequencies between 1 and
4%, and contribute to between 30 and >80% of the cases of congenital
sensorineural deafness in each of these populations. The high frequency
of these mutations has been variously attributed to founder effects, or
structural features of the genome (e.g. a string of repeated Gs in the
case of 35delG) that increase the likelihood of mutation. However, an-
other possibility that has been proposed is that these mutations could
confer some selective advantage [13]. 35delG and R75W carriers have
been reported to have a thicker epidermis [30,31], with the latter hetero-
zygotes also showing higher sweat salinity. These phenotypes may con-
fer a higher resistance to injury or microbial infection. This is also
consistent with an observation that Cx26 wt, but not the R75Wmutant,
rendered HeLa cells more subject to invasion by the gastrointestinal
pathogen, Shigella ﬂexneri [32].
Although the most frequently occurring NSHL mutations produce
severely truncated proteins due to frameshift or missense mutations,
almost 80% of the described deafness mutations are actually single
amino acid changes or deletions. As summarized in [12], these muta-
tions have been found in all domains of Cx26. However, the signiﬁ-
cance of this is unclear without any information on the functional
effects of these mutants. Fortunately, the last few years have seen in-
creasing numbers of these mutations characterized by expression in
exogenous systems like Xenopus oocytes or transfected mammalian
cell lines. Table 1 summarizes all of the NSHL (in black) and
syndromic deafness (red) associated mutations that have been func-
tionally tested in this fashion. Some variability in results have been
reported by different labs, perhaps because of different expression
systems, different modes of characterization or perhaps even varia-
tion in expression levels. In these cases, we have reported the result
which shows the higher level of function (e.g. formation of junctional
plaques over no gap junction formation).
Based on frequency of mutated residues (shown at the bottom of
Table 1), M2 shows the highest density of mutations associated with
NSHL (67%), followed by M3 (50%), E2 (43%), M4 (40%), NT, CL (36%),
M1 and E1 (33%). When the frequency of mutagenesis leading to all
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show higher than 50% mutation rates (NT, M2, M3, E1 and E2). While
still relatively broad, this selective concentration of mutations is likely
to have functional signiﬁcance that could then cast light on the roles
played by gap junctions in the ear.
Not surprisingly, the majority of mutants cause generalized folding
problems that result in failure in trafﬁcking of Cx26 to the cell surface,
or are permissive for the formation of gap junction plaques, but prevent
opening of the intercellular channels. As might be expected of muta-
tions that affect folding or conformational changes in a membrane
protein, all four transmembrane domains can be affected, although
M4 appears to be less important for channel function, consistent with
much of the literature. With the exception of the N-terminal domain,
which has been clearly implicated in the structure of the pore mouth
[33,34], the cytoplasmic domains do not appear to contribute to the
folding and trafﬁcking of the protein, although the cytoplasmic loop
region can affect channel opening. Perhaps most striking is the number
of mutations in the extracellular domains that can inﬂuence both chan-
nel function and trafﬁcking. The former is not too surprising, given the
importance of these regions in the docking of two hemichannels to
form a functional intercellular channel. Most of these mutants, with a
few notable exceptions discussed below, have not been tested for
their function as hemichannels. However, it is surprising the degree to
which these domains also appear to be critical to the correct folding
and trafﬁcking of the protein to the cell surface. This may be due to
failure of these mutants to form the correct disulﬁde bonding pattern,
which often serves as a measure of “quality control” in the folding of
many proteins.
Of greatest interest in terms of shedding light on the role of gap
junctions in the ear are the mutants that affect speciﬁc connexin func-
tions. Among NSHL‐associated mutants, ﬁve show selective changes in
the permeability of the channels, where ionic conductance and even
permeability to anionic ﬂuorescent tracers are maintained, but perme-
ability to larger molecules [cationic tracers (T8M and N206S — [35])
and inositol 1,4,5-trisphosphate (IP3) (V84L, A88S, V95M — [36,37])] is
compromised. The one Cx30 mutant associated with NSHL that has
been characterized also appears to be in this category, causing a reduc-
tion in IP3 permeability [37]. With one exception, all of these mutations
are in the NT andM2 domains. This is consistent with the implication of
these domains in the pore in recent structural models [33], although the
mutations in M2 all line up on a face of the helix that in structure face
away from the pore. However, the X-ray structure probably represents
that of a hemichannel, since the crystals were generated from connexins
puriﬁed under conditions that typically yield hexamers. By contrast, in
situ mapping of the pore domain of intact gap junction channels (Cx32
and 50) indicates that these residues do face the pore in gap junctions
([38], Toloue and Nicholson, unpublished results). These results suggest
that passage between cells of speciﬁc larger metabolites, rather than
ions, is critical to normal hearing. The signiﬁcance of this to the current
models of gap junction function in the ear is discussed below.
2.2. Cx26 mutations and syndromic deafness
GJB2 mutations have also been linked to syndromic hearing loss,
which is accompanied by a variety of mild to severe skin disorders.
The skin syndromes have been categorized into several types
according to their symptoms, including Vohwinkel syndrome (VS),
Bart–Pumphrey syndrome (BPS), palmoplanta keratoderma (PPK),
keratitis–ichthyosis–deafness syndrome (KID), and hystrix-like
ichthyosis deafness syndrome (HID). The ﬁrst three of these skin
diseases (VS, BPS and PPK) seem to represent a constellation of sim-
ilar phenotypes, involving palmoplanta hyperkeratosis (thickening
of the palms and soles of the feet). VS also includes notable constric-
tion bands around the digits that can lead to auto-amputation, and
BPS includes nail thickening and brittleness. KID and HID are similar
to one another, but distinct from the other three syndromes, in thatskin lesions are not restricted to any one region, and they include
hair loss (eyebrows and eyelashes) and ichthyosis that causes dis-
ruption of the dermal barrier and increased susceptibility to infec-
tion that can be lethal. KID also involves extensive keratitis that in
severe cases can lead to blindness.
In contrast to mutations associated with NSHL, all mutations causing
syndromic deafness are missense mutations and are inherited in a
dominant manner [39–42]. Since none of the complete loss of protein
mutants associatedwithNSHL cause skin problems, andCx26 conditional
knockout and Cx30-null mice also exhibit no skin phenotype, it is likely
that connexins in skin have redundant functions, so that lack of one
type of connexin would not cause skin disorders [43,44]. Since the
connexin alleles causing syndromic hearing loss are dominant, it is plau-
sible to speculate that these mutations cause disease through either a
transdominant effect on other connexin proteins expressed in the skin,
or through a speciﬁc gain-of-function that is not suppressed by any of
the other wt connexins expressed in the skin, of which there are nine.
Consistent with the clustering of the different skin syndromes into
similar groupings, Cx26 mutations which cause VS–BPS–PPK syn-
dromes show signiﬁcant overlap, and all have been found to have a
transdominant effect on other connexins expressed in the epidermis.
These mutations include ΔE42 (PPK), G59A (PPK), D66H (VS) and
R75W (PPK) [45,46]. Of these, G59S is associated with both VS and
BPS [47]. N54 is associated with BPS or PPK, depending on whether
it is mutated to a K or H, respectively [48,49]. As summarized in
Table 1, all of these mutations that have been characterized are loss
of function mutations with problems in trafﬁcking, or the formation
of functional gap junction channels.
Of the Cx26mutations causing themore severe HID–KID syndromes
that have been tested for function, with the exception of S17F, all have
been found to increase hemichannel activity (Table 1). Thesemutations
include G12R, N14K, A40V, G45E, D50N [50–52] and A88V (Xu and
Nicholson, unpublished results). Transgenic expression of Cx26G45E
inmice correlatedwell with humanKID pathology. Electrical recordings
showed increased hemichannel current [53]. Although all of the
mutations which lead to HID–KID cause increased hemichannel open-
ing, they seem to exert their effects through different mechanisms.
Cx26A40V alters hemichannel sensitivity to extracellular Ca2+, while
Cx26G45E, which was located in the pore using cysteine accessibility
(SCAM) studies, increases the hemichannel permeability to Ca2+ [54].
Our unpublished data demonstrates that A88V enhances hemichannel
surface expression without affecting other channel properties, thus
also causing larger hemichannel currents. Interestingly, other muta-
tions at this site (A88S) that increase hemichannel currents by affecting
voltage gating, but not surface expression, result only in hearing defects,
as the voltage gating of hemichannels is not a major mode of regulation
in the skin. Given that, in almost all exogenous expression systems,
these mutants result in compromised cell health due to constitutively
leaky hemichannels, it seems likely that cell death is a major source of
the etiology of the KID–HID spectrum of syndromes.
2.3. Other connexin mutations in deafness and skin disease — Cx30, 30.3
and 31
Mutations in three other beta connexin genes, GJB3 (Cx31), GJB4
(Cx30.3) and GJB6 (Cx30) have also been associated with various
forms of NSHL (Cx31 E183K, delI141, I141V and delD66; Cx30 T5M)
[55–57], syndromic deafness associated with erythrokeratoderma
variablis (EKV) (Cx31 G12D, R42P and C86S; Cx30.3 F137L) [58,59]
and a form of skin disease without accompanying hearing problems,
hidrotic ectodermal dysplasia (HED) (Cx30 G11R and A88V) [60]. EKV
presents with hyperkeratotic plaques and variable areas of erythema,
while HED (also called Clouston syndrome) involves hair loss, nail hypo-
plasia, hyper pigmentation and palmoplanta hyperkeratosis. The vast
majority of the mutations cause loss of function, with failure of the
protein to trafﬁc to the surface. In the cases associated with EKV, this is
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death [61]. In the NSHL cases, whether recessive or dominant, there was
typically no compromise to cell health, nor major loss of intercellular
coupling. As shown in Table 1, the HED‐associated mutants, like those
in Cx26 that caused KID syndrome, caused an increase in hemichannel
activity that likely results in increased cell death ([62], Xu andNicholson,
unpublished results).
3. Function of connexins in the ear
3.1. Connexin distribution in the ear
RNA expression for a number of connexins has been detected in the
cochlea (Cxs26, 29, 30, 31, 43, 30.2, 37 and 46 — [63,64]), however,
immunocytochemistry has only conﬁrmed expression in a few of these
cases. Cx26 and Cx30 are the most abundantly expressed, primarily in
the supporting cells, ﬁbrocytes in spiral limbus and spiral ligament, and
stria vascularis of both humans and rodents [65–67], but not in the
inner or outer hair cells or the marginal cells of the stria vascularis
[63,66–68]. Cx29 is found primarily in myelinating glial cells [69],
although it has been detected in low levels in the stria vascularis [70].
Reports of Cx31 expression have been varied, but it has been reported
to have some overlapping expression with Cx26 and 30 in ﬁbrocytes of
the spiral ligament and limbus [71] and below the spiral prominenceTable 1
Cytoplasmic
Defect Cx
NT CL CT M1
No GJ formation
M1V
G12V
N14D
S19T
I35S
channel function
G12R
N14Y k
S113R
ΔE120
E114G
I33T
M34T
M34A
Cx26
T8M
Permeability
Cx30 T5M
Cx26
G12R k
N14K  k
A40V  k
Aberrent 
hemichann
el function Cx30 G11R  h
total mutants
(Cx26) 8−3 12−1 3 6−1 
Total residues 22 35 18 18
No/reduced S17F   k R127H V37I
[1]
[2, 3]
[4]
[2]
[5]
[18]
[17]
[18, 19]
[7]
[7]
[1, 2, 9, 20]
[21]
[5]
[1, 2, 8, 15, 22-24]
[7, 9]
[15, 25]
[31]
[32]
[18]
[18]
[34]
[35][68]. Cx32, 43 and 45 are all expressed in the cochlea earlier in develop-
ment, but expression is either lost (Cx32 — [72]) or redistributed to the
expected locations (bone for Cx43 [73], capillaries for Cx45).
In terms of the major connexins, Cx26 and Cx30 show ex-
tensive co-localization immunocytochemically [63,74,75]. Their
co-immunoprecipitation, both from cochlea tissue and exogenously
expressing cell lines, also supports the existence of Cx26/Cx30
heteromeric channels [63,74–76]. At the prenatal stage, staining is
concentrated to narrower bands of cells in the spiral limbus and spi-
ral ligament, but absent in the supporting cells [75]. After birth,
connexin expression gradually increases in the supporting cells of
the cochlea [75,77]. Prior to P8, immunostaining indicates that only
Cx26 is expressed in the Claudius cells, Hensen's cells and inner sul-
cus cells, although both Cx30 and Cx26 are distributed in the outer
sulcus regions [78]. The most dramatic change postnatally is that
Cx30 then replaces Cx26 in the supporting cells surrounding the
outer hair cells (Dieters' and Hensen's cells) between P0 and P12
[75,77]. The function of gap junction channels is also very dynamic
during development, as suggested by dye transfer studies [77].
3.2. Functional properties of the major cochlear connexins (Cx26 and 30)
While Cx26 and Cx30 share high sequence homology, they have
been found to have quite different permeability properties. Cx26Membrane Extracellular
M2 M3 M4 E1 E2
W77R
I82M
V153I L214P W44C/S
T55N
G59V/H/R p
C64S[15]
D66H v
H73R p
M163V/L
P173R
S183F
R184P
L214P
W77R
L90P
T135A
R143W/Q
ΔE42 p
W44C
R75W/D/Q p
D50N          k
G59A p
F161S
W172R
R184Q
M163V
C202F
V84L
A88S
V95M
N206S
A88S 
A88V k
G45E          k
D50N         k
(R75W)
A88V h
14−1 13−1 8 12−8 13−1 
21 26 20 36 30
E47K D179N
[6-8]
[9]
[10] [10] [6, 11, 12]
[13]
[9, 11, 14]
[11, 12, 14]
[16]
[7]
[1]
[16]
[1, 7] 18941476
[10]
[7]
[1, 2, 7, 9]
[26]
[7, 9, 10, 20]
[12]
[8]
[27]
[5, 11, 12, 15, 25, 28],
[18]
[1]
[5]
[29, 30]
[29, 30]
[7]
[29, 30]
[20, 32, 33]
[32]
[20, 32]
[31]
[36]
[36]
[27, 34]
[18]
[35]
Notes to Table 1:
Black = non-syndromic hearing loss (NSHL).
= syndromic hearing loss: K = keratitis–ichthyosis deafness syndrome (KID).
p = palmoplanta keratoderma (PPK); V = Vohwinkel syndome (VS).
= hidrotic ectodermal dysplasia (HED)/no hearing loss.
(…) = hemichannels are functional, but not necessarily enhanced compared to wt (gap junctions non-functional).
Bold — dominant inhibitory effect on other connexins.
NT — amino-terminal domain (20 aa).
CL — cytoplasmic loop (38 aa).
CT — C-terminal domain (17 aa).
M1–M4: transmembrane domains 1 through 4 (~20 aa each, except M3 which is ~26 aa).
E1–E2: extracellular loops 1 (~35 aa) and 2 (~28 aa).
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charged dyes, Lucifer yellow, calcein, and carboxyﬂuorescein, but
Cx30 gap junction channels are largely impermeable to these mole-
cules, even when comparisons are made between cells with very sim-
ilar electrical coupling. In contrast to the anionic dyes, both connexin
gap junctions are equally permeable to positively charged dyes like
ethidium bromide or propidium iodide [76,79,80]. Cx26 was also
found to mediate Ca++ wave propagation between cells more efﬁ-
ciently than Cx30 [36]. Based on their extensive co-localization in
the cochlea, Cx26 and 30 have also been co-expressed in exogenous
systems, yielding single channel conductances and gating behavior
not observed between cells expressing only one connexin [76]. This
strongly indicates the existence of heteromeric channels, consistent
with co-immunoprecipitation of these two connexins in the ear
[63,75,76]. In terms of permeability to dyes, these heteromeric chan-
nels appear to be dominated by Cx26 [75,76], and show even faster
Ca++ wave propagation than cells coupled by Cx26 alone [75].
Thus, it seems possible that heteromeric channels can gain unique
permeability properties not shown by either homomeric channel. In
situ, it is difﬁcult to predict what proportions of homomeric and
heteromeric channels exist, although this is likely to vary between
different parts of the cochlea where the relative levels of the two
connexins differ, such as Dieters' cells in adult mice, which primarily
express Cx30.
3.3. Insights from mouse genetic models
To understand the physiological functions of the gap junctional
network in the cochlea, and how defects in it cause deafness, mouse
genetic models have proven invaluable tools. However, the mouse ge-
netic models only reproduce the most profound and simpliﬁed symp-
toms seen in the human patients carrying connexin mutations, thus
caution in interpreting them needs to be exercised in light of differ-
ences that exist in mouse and human physiology, and how (and
when) connexin function was disrupted. In particular, the range of
clinical phenotypes resulting from Cx26 mutations is generally
much larger than has been reported to date in mice, ranging from
pre-lingual to progressive and late onset deafness of varying sever-
ities. Such variations have even been seen between siblings with the
same Cx26 mutation [81], indicating that some of this variation is
due to the diversity of genetic background present in the human pop-
ulation, but not mimicked in lab mouse models.
Several mice lines have been developed to study Cx26 function, but
since germline Cx26 knockout is lethal in mice due to its requirement
for placental function [82], two conditional Cx26 knockout mice were
developed. One is a spatially speciﬁc knock out, which used the Otog
promoter to speciﬁcally delete Cx26 in the epithelial cells. The other is
a temporal knockout, which utilized a ligand inducible recombinase to
delete Cx26 after E19 [83,84]. Bothmice lines display moderate hearing
loss and hair cell degeneration, but the cell death in the latter line is
more rapid and extensive. Cell degeneration of spiral ganglion neurons
was also observed in the latter line. Cell degeneration in the former line
starts from the inner hair cells, while in the latter line it starts form the
outer hair cells. The endolymphatic potential (EP) of these mice is min-
imally affected at P12,when the organ of Corti development is complete
and the EP reaches mature levels [85], but drops to one-third wt levels
in the adult, with a 50% loss in K+ concentration in this compartment.
The signiﬁcance of this for the function of the ear will be discussed
below. Another mouse genetic model of deafness utilized the knock-in
of a dominant disease mutation, Cx26R75W. Due to its well character-
ized dominant-negative effect on gap junction channel function, trans-
genic expression of themutant protein [43], or its transient transfection
into the ear of adult mice [86], should serve to ablate all endogenous
gap junction function. These mice show quite different phenotypes,
with the former showing severe hearing loss and outer hair cell loss,
and the latter rather minor hearing effects and no loss of hair cells,suggesting that expression of the mutant connexin over the lifetime of
the mouse contributes to disease. Other effects on SG neuron degener-
ation in thesemodels are likely due to their broader expression patterns
in the cochlea, compared to the knock-outs, whichwere targeted to the
epithelial system. There are also reports that expression of this mutant
can lead to arrested development of the organ of Corti, [87], an effect
also reported in some Cx26 conditional knock-outs [78,88]. This sug-
gests that cx26 signaling may also be important to different aspects of
development of this part of the ear.
Cx30 null mice were generated by deletion of the Cx30 coding re-
gion [44]. These mice show signiﬁcant hearing loss, accompanied by
hair cell loss, and failure to develop an EP, even though K+ levels
are elevated in the endolymph. Hair cell degeneration occurs after
P18 and the outer hair cells are damaged more severely. Cx30T5M
knock-in mice were also generated due to the interest that this muta-
tion speciﬁcally impairs biochemical coupling of the cells, while leav-
ing electrical coupling intact [89]. These mice display mild deafness,
but nonetheless show a signiﬁcant increase of hearing threshold.
Interpretation of these knock-out studies is complicated by the
ﬁndings that loss of either connexin results in a decrease in the ex-
pression level of the other, apparently through a PLC–NF-κB sig-
naling mechanism, although it is not clear how Cx26 and Cx30
expression could affect this pathway [90]. The reciprocal regula-
tion of Cx26 and Cx30 could also be due to their direct interaction,
which might stabilize them and extend their half-life on the plas-
ma membrane. Thus, it was unclear if any of these knock-out phe-
notypes should be interpreted in terms of loss of the properties of
a speciﬁc connexin (or speciﬁc heteromeric forms), or just gener-
alized reductions in coupling. To investigate this, two recent stud-
ies tested the effect of replacing one connexin with another. Most
instructive was the ﬁnding that deafness caused by loss of Cx30
could be corrected by over-expression of Cx26 through a BAC
chromosome, thereby re-establishing the original coupling levels,
but now with only one connexin isotype [91]. In contrast, BAC ex-
pression of Cx30 failed to rescue the morphological or hearing
phenotype of Cx26 null mice [78], demonstrating that Cx26 chan-
nels are necessary, while Cx30 channels are not sufﬁcient, for nor-
mal hearing. It has been suggested that the earlier expression of
Cx26 than Cx30 in the supporting cells (Cx30 is ﬁrst seen at P6)
could be the reason why Cx26 is indispensible, and its knock-out
causes more severe phenotypes and earlier cell degeneration
than seen in Cx30-null mice. Alternatively, the more restrictive
permeability of Cx30 channels to larger anions may limit its ability
to replace Cx26. In this regard, it has recently been shown that re-
placement of Cx26 with Cx32 in a knock-out mouse, results in a
normal hearing phenotype [92]. Thus, while Cx26 has unique
properties that it apparently does not share with Cx30, they are
sufﬁciently mimicked by Cx32 to maintain ear function. Intriguing-
ly, Cx26 and Cx30 share much closer sequence homology than
Cx26 has with Cx32, demonstrating that the properties that are
important to preserve are likely dictated by a small part of the
connexin structure. These results suggest that both net levels of
expression of connexins, as well as their speciﬁc properties, are
critical for the auditory function of the ear.
3.4. Proposed models for gap junction function in the ear — insights from
functional deﬁcits of connexin deafness mutants
Cx26 and Cx30 form two gap junction networks in the cochlea:
the epithelial cell system and the connective tissue cell system. Epi-
thelial cells include supporting cells from interdental cells medially
to the outer sulcus cells laterally. Medially, the epithelial GJ system
connects inner hair cells to the endolymph through the interdental
cells or the extracellular space of the spiral limbus. Laterally, this sys-
tem connects the basolateral space of outer hair cells to the spiral lig-
ament extracellular space. The GJ system in the connective tissue then
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space (Fig. 1A). As most of the GJB2 and GJB6 mutations disrupt gap
junction coupling, it is apparent that this network of intercellular
communication is important for the normal function of the cochlea.
The recessive nature of most connexin deafness mutants indicates
that they do not affect the expression or function of other connexins,
even the product of the wt allele in a heterozygote. This would indi-
cate that loss of any one connexin is sufﬁcient to induce disease,
and there is little “redundancy” in the cochlea, in contrast to skin dis-
ease discussed below where most mutants are dominant.
However, the fact that gap junction channels are permeable to a
wide spectrum of molecules makes it difﬁcult to deﬁne their exact
functions in any system, including the ear. Some clues, however,
have been provided by disease mutants that have caused more specif-
ic loss of selective functions of the protein, as summarized in Table 1.
The insights that these, along with mouse studies described above,
have provided into connexin function in the cochlea are summarized
below in the context of some of the models that guide current
thinking.
3.4.1. K+ recycling
The apical side of hair cells and supporting cells faces the endo-
lymph, which contains a low concentration of Ca++ (20 μM), but
high concentrations of K+ (>100 mM), that can be maintained
when the endolymph and perilymph are electrically isolated from
one another via tight junctions between the basal cells of the stria.
This occurs in mammalian systems, and results in a positive endolym-
phatic potential (EP) of 100–150 mV. Sound stimulation opens
mechanosensitive channels to allow K+ to enter the hair cell from
the endolymph. Since the cytoplasm of the hair cell has a typical rest-
ing potential of−80 mV, the electromotive force driving the K+ cur-
rent is substantially higher than seen in most neurons where the
extracellular environment is at ground, thus amplifying the inward
K+ current across the membrane. The receptor potential generated
causes neurotransmitter release from hair cells, as well as K+ release
into interstitial space, possibly through KCNQ4 channels. This excess
extracellular K+ is then absorbed by the supporting cells through
the KCC4 K+/Cl− co-transporter [93–95]. Mutations in KCNQ4 or
KCC4 are known to cause deafness due to hair cell degeneration.
Since cell loss only occurs after hearing onset in conditional GJB2,
and KCC4 knockout animals, it has been proposed that high local ex-
tracellular K+ levels are toxic to hair cells by depolarizing their mem-
brane potential, and producing hyperexcitability in the cells. This is a
well established phenomenon in other neuronal populations, and the
gap junction network connecting astrocytes has been implicated in
the buffering of this extracellular K+. This is also likely to be true in
the supporting and epithelial cells of the cochlea, and its failure
would lead to hair cell loss after they become active.
However, in the ear this uptake and intercellular distribution of
K+ may have another role. The EP described above is ﬁrst generated
several days prior to the onset of hearing, and reaches adult levels at
the onset of hearing at P12, K+ from the stria intermediate cells is se-
creted into the intrastrial space by KCNJ10 (Kir4.1) [96,97], from
where marginal cells absorb it by a Na+/K+/2Cl− co-transporter,
NKCC1, and secrete it into the endolymph by the PIP2 regulated K+
channel (KNCQ1/KCNE1 — reviewed in Ref. [98]). The K+ secretion
from the stria intermediate cells is thought to be the end product of
“recycling” of K+ initially released from hair cells, through the epithe-
lial and connective tissue gap junction networks [99,100]. Gap junc-
tion coupling between ﬁbrocytes is established as early as P2.
Coupling between ﬁbrocytes and basal, as well as intermediate cells,
in the stria vascularis, is established by P7 inmammals [101] and is re-
quired for completion of the K+ recycling “circuit” by bypassing the
extracellular tight junction barrier between the stria and the
perilymphatic space of the spiral ligament. Thus, gap junction systems
in the cochlea may be responsible for both K+ clearance from the haircells, and EP formation.While the former is generally accepted, several
lines of evidence have been used argue against a role for the GJ net-
work in the epithelia cells contributing to EP formation. Firstly,
Cx30-null mice do not develop normal EP, but maintain electrical cou-
pling between supporting cells [44,102]. Cx30T5M transgenic mice,
mimicking a form of NSHL (Table 1), also show impaired hearing,
but normal electrical coupling between supporting cells as measured
by double electrode patch clamp [89]. Secondly, knockout of Cx26 in
epithelial cells, or transgenic expression of the dominant deafnessmu-
tant, Cx26R75W, does not impair initial EP development, but still
cause deafness [43,83], and Cx26 mutants like V84L, which, like
Cx30T5M, shows normal electrical coupling, still show hearing loss.
Thirdly, knockout of KCC4, which is the transporter in the supporting
cells to siphon K+ secreted fromhair cells into epithelial cells, does not
show the collapse of Reissner'smembrane, which is always seen in an-
imals with impaired K+ secretion from stria vascularis, but still show
hair cell degeneration [93].
The problem with these conclusions is that they often presuppose
that the K+ recycling in the cochlea might occur through direct pas-
sive diffusion of K+ ions. However, this is unlikely, as such diffusion
would be unlikely to propagate over any distance unless it was part
of a regenerating system. Such a system could be provided through
intercellular Ca++ waves known to occur in the cochlea (Fig. 1B). In
this model, an initial Ca++ response generated by depolarization
from initial K+ uptake, would generate an IP3 response through stim-
ulation of PLCδ. The IP3 could then pass through gap junctions to a
neighboring cell, where it would, in turn, activate Ca++ release from
intracellular stores, and initiate the whole process again. Ultimately,
this Ca++ response can also trigger opening of Ca++‐sensitive K+
channels at the apical surface of root cells into the extracellular
space of the spiral ligament (end of the endothelial cell propagation)
or from the connective tissue system into the intrastrial space where
it can be taken up by the marginal cells. An alternative, extracellular
route also could involve connexins. The same initial Ca++ signal
could induce opening of hemichannels, resulting in ATP release from
the cell. Diffusion of this ATP to the neighboring cell would activate
P2Y receptors, which would then generate an IP3 signal through
G-protein mediated activation of PLC, producing a Ca++ spike that
would then regenerate the same cycle in that cell. Thus, both extracel-
lular and intercellular Ca++ waves are both mediated by connexins
and could provide the means of propagating a signal over a long dis-
tance that could effectively shuttle K+ from its release from hair
cells back to the endolymph. Both mechanisms of Ca++ wave propa-
gation, which is proposed to mediate this regenerative K+ ﬂow, have
been demonstrated in the immature cochlea [103].
These models explain many of the observations above that had
seemed contradictory to the K+ recycling model. While several of
the knock-outs (Cx30 or Cx26) had appeared to leave electrical cou-
pling intact, this is difﬁcult to quantify with the complex connectivity
of cells seen in situ. Furthermore, the above model would indicate
that it is not ion ﬂow that is relevant, but that of larger molecules
like IP3 and ATP, the ﬂux of which is likely to be more sensitive to a
reduction in channel number than electrical coupling. This would
also explain why mutants such as Cx26V84L, A88S and V95M as
well as Cx30T5M, all of which selectively ablate IP3, but not ionic, per-
meability cause deafness. It also likely explains why Cx30 cannot
replace loss of Cx26, while Cx26 can replace loss of Cx30 in the trans-
genic mice experiments described above, since Cx30 homomeric
channels have been shown to be much less permeable to large anions,
including IP3, than Cx26 homomeric channels, or heteromeric chan-
nels of Cx26 and 30 [36]. The Cx26R75W mutation was shown to
still allow development of the EP, even in the absence of gap junction
channels [43]. However, its ability to form hemichannels remains in-
tact [104], so that it is possible that at least the K+ recycling function
could be preserved through the extracellular route of ATP release.
Thus, in the light of these regenerative models of Ca++‐wave
Fig. 1. A. Diagram of the cochlea and its various compartments, showing the proposed return of K+ (possibly mediated by a propagated Ca++ wave) from the hair cells to the en-
dolymph (red arrows) through the epithelial (green color) and connective tissue (dotted box) gap junction networks. The former is comprised of Dieters' cells and supporting cells,
while the latter is comprised of types I and II ﬁbrocytes in the spiral ligament and basal and intermediate cells of the stria vascularis. Ultimately, released K+ is taken up by the
marginal cells of the stria vascularis and released into the endolymph, thus maintaining the elevated K+ levels (and high resting potential of ~+100 mV) in this compartment.
This is essential for amplifying the responses of hair cells to sound, by increasing the driving potential for K+ ﬂux across the hair cell membrane when it is activated. B. Possible
models to explain how K+ is recirculated in the ear are:
I. Passive K+ ﬂux through gap junctions. This seems unlikely, as it would decay over a relatively short distance.
II. A regenerative Ca++ wave that is propagated by IP3 ﬂux between cells. IP3 is regenerated in each cell by IP3‐induced Ca++ release from intracellular stores that activates phos-
pholipase C (PLC). Ultimately, in the stria vascularis, K+ is released into the intrastrial space or the endolymph through KCNJ10 (Kir4.1) or PIP2 regulated (KNCQ1/KCNE1) K+
channels.
III. A regenerative Ca++ wave that is propagated extracellularly by Ca++ activated release of ATP through connexin hemichannels which then activates P2Y receptors in adjacent
cells. These in turn can activate PLCδ, which will generate IP3 and re-initiate the Ca++ response.
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tants and human disease mutations are consistent with at least one
of the critical roles of connexins in the cochlea being to remove K+
from the vicinity of the hair cells and return it to the endolymph.
3.4.2. Metabolite transfer
Aside from their role in propagation of Ca++ waves, gap junctions
have also been shown to pass non-signaling permeants, including nu-
trients, such as amino acids and glucose. Since the organ of Corti is an
avascular organ, gap junction channels in supporting cells and con-
nective tissue cells may be critical for the energy supply of the co-
chlea, in a manner similar to that proposed for the eye lens [105].
Consistent with this, Cx30-null mice were found to have impaired
permeability to 2-NPDG, an analog to D-glucose, and to display in-
creased ROS production [102]. This is consistent with the contention
that decreases in coupling that go undetected electrically, could still
impair larger metabolite/nutrient transfer to the point of compromis-
ing cell health. Finally, it should not be forgotten that non-canonical
permeants larger than 1 kDa, including short peptides [106], siRNA
[107] and miRNA [108,109] have also been shown to pass through
gap junctions. Such signaling, which has not been investigated in
the case of the cochlea, may be critical for cochlear homeostasis,
and contribute to the variations seen in deafness phenotypes be-
tween different connexin mutants.
3.4.3. A role for hemichannels?
So far, there have been no reports speciﬁcally indicating loss of
hemichannel function involved in the etiology of connexin‐linked
congenital deafness. If there are connexin mutations which cause dis-
eases due to loss of hemichannel function, one of the reasons why
they may have not been identiﬁed is possibly because mutations
which impair hemichannel functions would very possibly compro-
mise the gap junction channel function as well. However, several
deafness mutants have been identiﬁed that show normal gap junction
function, but enhanced hemichannel function (Table 1). As noted
above, hemichannels likely represent one of the major mechanisms
for generation of propagatable Ca++ waves in the cochlea though re-
lease of ATP. ATP release from the Kolliger organ through
hemichannels has also been suggested to be responsible for sponta-
neous hair cell activity before hearing onset [110]. The existence of
a hemichannel population was supported by immunostaining of the
apical surface of supporting cells by antibodies targeting the extracel-
lular loops of Cx26 [111]. It is also worth noting that, while the endo-
lymph has very high K+ levels, its Ca2+ levels are very low, around
~20 μM, which would facilitate hemichannel opening. Therefore, the
hemichannel functions in the cochlea warrant closer attention.
Of course, other than changes in nutrient and signal transfer, a
likely consequence of signiﬁcant increases in hemichannel activity
in the cochlea is increased cell death. Hemichannel opening is strictly
regulated by the cell through a combination of membrane potential,
high extracellular Ca++ and limited expression of unopposed
hemichannels at the cell surface. This is presumably because wide-
spread opening of large, relatively non-selective pores on the cell sur-
face would compromise cell health. Given that hair cells do not
express Cx26 or 30, it is unlikely that mutants of these genes with en-
hanced hemichannel function contribute directly to the hair cell
death seen in patients and mice models. However, they could com-
promise the functional integrity, or even cause cell death [83] in the
supporting parts of the cochlea, which would then lead indirectly to
hair cell death. Cell death can also arise through accumulation of un-
folded proteins in the cell that can lead to a pathogenic unfolded pro-
tein response. This may be the underlying cause of deafness with
several connexin mutations which show no evidence of enhanced
hemichannel activity, but instead accumulate expressed protein in-
tracellularly (e.g. Cx31 G12D — [61]).3.4.4. Relative roles of Cx26, 30, 30.3 and 31
There are many fewer mutations found on GJB6, 4 and 3 associat-
ed with deafness. Most of the GJB6 mutants associated with NSHL are
deletion mutants, which likely lead to premature termination of the
protein [112–114], and provide little insight into their functional im-
portance. These deletions are typically homozygous, compound het-
erozygous or trans-heterozygous with a Cx26 recessive mutation,
suggesting that deafness may only result when not only Cx30 func-
tion is lost, but also Cx26. Larger deletion mutations, which truncate
GJB6 (Cx30), may also affect the transcription level of the neighboring
Cx26 gene in an allele‐speciﬁc manner, should they also affect the
cis-regulatory elements of the Cx26 gene [115,116]. These observa-
tions are all consistent with mouse models which indicate that in-
crease in Cx26 expression can alleviate the deafness phenotype of
Cx30 knock-out mice [91].
The exceptions to these NSHL‐associated deletion mutations are
Cx30T5M [57] and Cx30A40V [117]. Only Cx30T5Mhas been functionally
characterized, being shown to have reduced permeability to IP3 [37], sim-
ilar to several of the NSHL causing Cx26 mutations (Table 1). Two other
point mutations of Cx30, one in the NT (G11R) and the other in M2
(A88V), causeHED, a skin diseasewith aspects of both PPK (hyperkerato-
sis of palms and feet) and KID (hair loss), butwith no hearing phenotype.
Both mutants cause increased hemichannel opening, as do several of the
mutations of Cx26 associated with KID syndrome. However, since these
Cx26 mutations do show a hearing phenotype, this suggests that either
Cx30 hemichannels may be differentially regulated in the ear, and/or
that similar mutations in Cx26 and 30 (e.g. A88V) have different effects
in channel function in the two isotypes.
Mutations in GJB4 (Cx30.3) and GJB3 (Cx31) associated with both
NSHL (Cx31-E183K, ΔI141 and I141V) and syndromic deafness linked
to EKV (Cx30.3F137L and Cx31 G12D, R42P and C86S) or peripheral
neuropathy (Cx31ΔD66) [55,56,58,59,118,119] fail to produce func-
tional channels, with the proteins typically accumulating in the cyto-
plasm. Thus, they cast little light on the functional roles of these
connexins in the ear or skin. It is notable, however, that the mutants
associated with EKV accumulate sufﬁciently in the cytosol in exoge-
nously expressed systems to lead to cell death.
4. Function of connexins in the skin
As noted above, most of the mutations associated with NSHL are
inherited recessively, while those which also cause skin disease are
dominant, even when the mutations are in the same regions of the
protein, and cause similar disruption in trafﬁcking of the protein to
the cell surface or formation of functional gap junction channels
(ﬁrst two rows, Table 1). This suggests that, unlike the ear where at
least Cx26 seems essential for normal function, there may be redun-
dancy in the skin. Thus, loss of any one connexin is not deleterious,
unless it also affects other connexins with which it interacts. Consis-
tent with this conclusion is the frequency of mutations that cause
dominant effects on co-expressed connexins (bold type in Table 1),
which is much higher among syndromic than non-syndromic deaf-
ness mutations of Cx26 (5 of 8 compared to 5 of 38 sites character-
ized, respectively, in ﬁrst 2 rows of Table 1). Such a conclusion is
not surprising, given the much higher abundance of different
connexins with overlapping expression patterns in the skin, where
Cx26, 30, 30.3, 31, 31.1, 37. 40 and 43 are broadly distributed, with
differing patterns during development [120–123].
The speciﬁc functions of gap junctions in the skin remain largely
obscure to date. They have been implicated in the formation of com-
munication compartments among keratinocytes that could correlate
with epidermal proliferative units during development [124], poten-
tially explaining the hyperkeratosis seen in many connexin‐associat-
ed skin phenotypes. However, this is likely to be complex, as the
upregulation of Cx26 expression, not its loss, is associated with skin
thickening in response to retinoids [125], and thickening of mouse
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wound healing has also been extensively studied, with elevation of
Cx26 and 30, and reduction in Cx31.1 and 43, occurring successively
following wounding [127–129]. The functional relevance of this has
been demonstrated using topical Cx43 knockdown, which results in
signiﬁcant enhancement of wound healing rates in several model sys-
tems [123,124,130,131].
As discussed above for the NSHL mutations, the greatest insight
into the speciﬁc functions of Cx26 or other connexins in the prolifer-
ative or wound healing responses of skin would be provided by mu-
tations that selectively change speciﬁc properties of the channels.
Notably, none of the mutants of either Cx26 or Cx30 that change
the permeability properties of gap junction channels cause any skin
problems (third row of Table 1). However, before concluding that
metabolite transfer through gap junctions is not critical for skin func-
tion, it is possible that the effects of these mutants could be masked,
as none of them have been shown to have dominant effects on
other connexins with which they are co-expressed.
In contrast, another manner in which a connexin‐disease mutant
could have dominant inheritance, other than dominant negative ef-
fects on wt connexins, is if the mutation induces a gain of function.
Thus, it is not surprising that almost all of the mutations of Cx26
that cause an increase in hemichannel activity, cause syndromic deaf-
ness (fourth row of Table 1), mostly associated with the more severe
KID syndrome. Even the two mutations of Cx30 that cause increased
hemichannels opening (G11R and A88V — [60,132]) cause skin dis-
ease, which in this case is not associated with deafness (HED or
Clouston's syndrome). This disease has features of KID (keratosis
and involvement of hair follicles), but also of the other cluster of syn-
dromes, PPK (thickening of the epidermis on the palms and feet) and
BPS (nail thickening). While the speciﬁc effects of increased
hemichannel opening in keratinocytes in situ has not been directly
assessed, it seems likely that this would lead to increased cell death,
as it does in the ear [62]. The one case of a mutant that increases
hemichannels function, but does not cause skin disease (Cx26A88S),
causes a loss of hemichannel voltage gating, which is likely an impor-
tant regulator in the ear, but not keratinocytes, which have very low
membrane potentials (Xu and Nicholson, personal observations).
5. Prospects for the future
While we do not have all of the answers as to how gap junctions or
hemichannels contribute to the normal function of the ear or skin, the
functional analyses of disease‐associated mutants summarized above
have stimulated a new era of discovery in this area. As more mouse
models are developed, and functional analyses of diseasemutants in ex-
ogenous systems expand to include detailed permeability analyses for
metabolites and signaling molecules, we will certainly gain a greater
understanding of how gap junction networks serve to integrate cochle-
ar and epidermal functions. Even structural information on these chan-
nels will prove relevant once we reach the resolution where we can
make predictions as to the functional effects of different mutations on
both hemichannel and gap junction conformations of these channels.
The insights we have already gained from this provide a compelling ar-
gument for the integration of the most basic molecular studies of gap
junction properties with in vivo analyses of mutant phenotypes, as
only then are we likely to truly understand the molecular basis of
organ function. Such insights will also be essential to developing truly
effective therapeutic strategies.
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